Clinical Roundup Degradation of HER2, EGFR may overcome drug resistance in HER2-positive breast cancers May 31, 2024Vol.50 No.22
Clinical Roundup PKMYT1 is a potential target for treatment-resistant ER+ breast cancers May 31, 2024Vol.50 No.22
Clinical Roundup Circadian clock can be leveraged to enhance cancer immunotherapy May 31, 2024Vol.50 No.22
Clinical Roundup Keytruda improves OS for high-risk early-stage TNBC in phase III trial May 31, 2024Vol.50 No.22
Clinical Roundup Scemblix improves MMR rates for Ph+ CML-CP in phase III trial May 31, 2024Vol.50 No.22
Clinical Roundup Kisqali reduces risk of cancer recurrence for HR+/HER2- early breast cancer in phase III trial May 31, 2024Vol.50 No.22
Clinical Roundup REGN7075 + Libtayo leads to anti-tumor responses in MSS colorectal cancer in dose-escalation portion of phase I/II study May 31, 2024Vol.50 No.22
Clinical Roundup Lifileucel + pembrolizumab show promise for advanced melanoma in data from phase II study May 31, 2024Vol.50 No.22
Clinical Roundup Combination therapy improves PFS, OS for metastatic colorectal cancer in phase Ib/II study May 31, 2024Vol.50 No.22
